ARTL
ARTELO BIOSCIENCES, INC.Company Information
- Company Name
- ARTELO BIOSCIENCES, INC.
- CIK
- CIK0001621221
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ARTL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ARTL
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-08-12
- Last sale
- —
- Shares purchased (TTM)
- 2,400
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 117,117
- Shares outstanding
- 673,008
- Ownership
- 17.40%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -8.44%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 4 | 10 | 1 | 2 | 2 | 1 | 2 | 4 | 1 | 1 | 3 | 3 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 4 | 10 | 1 | 2 | 2 | 1 | 3 | 5 | 6 | 8 | 11 | 13 | ||||||
| Marketable Securities | - | - | - | - | - | - | 0 | 1 | 5 | 6 | 8 | 10 | ||||||
| Deferred Costs | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Finite Lived Intangible Assets Net | - | - | - | - | - | - | - | - | - | - | 2 | - | ||||||
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 6 | 13 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 10 | 13 | 15 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 4 | 3 | 4 | 5 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 1 | 6 | 4 | 5 | 6 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Notes Payable | - | - | - | - | 1 | - | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Convertible Notes Payable Current | 0 | 0 | 0 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Derivative Liabilities Current | - | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability | - | - | - | - | - | - | - | - | 0 | 0 | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
| Liabilities | 1 | 6 | 4 | 5 | 6 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 5 | 7 | -1 | -1 | -1 | 1 | 3 | 6 | 7 | 10 | 12 | 15 | ||||||
| Additional Paid In Capital | 74 | 73 | 62 | 58 | 55 | 53 | 53 | 53 | 53 | 53 | 52 | 52 | ||||||
| Retained Earnings Accumulated Deficit | -68 | -66 | -63 | -59 | -56 | -53 | -50 | -46 | -45 | -43 | -40 | -37 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 6 | 13 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 10 | 13 | 15 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Debt Securities Available For Sale Amortized Cost Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 167 | 167 | 500 | 500 | 8 | 50 | 500 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 4 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialARTELO BIOSCIENCES, INC. (ARTL) — SEC Financial Statements & Analysis
ARTELO BIOSCIENCES, INC. (ARTL) is a pharmaceutical preparations company, incorporated in NV. ARTELO BIOSCIENCES, INC. trades on Nasdaq as: ARTL. ARTELO BIOSCIENCES, INC. (ARTL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, ARTELO BIOSCIENCES, INC. carries a market cap of $42.22M, a P/E ratio of -3.28x, a P/B ratio of 8.45x, an enterprise value of $38.02M, and an EV/EBITDA multiple of -3.33x. On profitability, it posts a Return on Equity (ROE) of -717.29%, a Return on Assets (ROA) of -238.15%, and a Return on Invested Capital (ROIC) of -204.74%. Per share, it reports EPS of $-3.07, diluted EPS of $-4.75, free cash flow per share of $-2.03, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 31.07% year-over-year and EPS growth of -92.65% year-over-year. On the balance sheet, it maintains a current ratio of 3.00x, a quick ratio of 2.89x, working capital of $2.92M, a debt-to-equity ratio of 0.29x, a debt ratio of 0.23, an interest coverage ratio of -47.52x, free cash flow of $-8.52M (TTM), and net debt of $-4.20M. Figures sourced from SEC EDGAR.
- Market Cap
- $42.22M
- P/E TTM
- -3.28x
- EPS TTM
- $-3.07
- P/B TTM
- 8.45x
- ROE TTM
- -717.29%
- ROA TTM
- -238.15%
- Debt To Equity
- 0.29x
- Free Cash Flow TTM
- $-8.52M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ARTELO BIOSCIENCES, INC. in?
ARTELO BIOSCIENCES, INC. (ARTL) operates in the Pharmaceutical Preparations industry.
What exchange does ARTL trade on?
ARTELO BIOSCIENCES, INC. (ARTL) trades on the Nasdaq.
Where is ARTELO BIOSCIENCES, INC. incorporated?
ARTELO BIOSCIENCES, INC. is incorporated in NV.
When was ARTELO BIOSCIENCES, INC. (ARTL)'s most recent SEC filing?
ARTELO BIOSCIENCES, INC. (ARTL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ARTL's market cap?
ARTELO BIOSCIENCES, INC. (ARTL) has a market capitalization of $42.22M as of 2026-06-30.
What is ARTL's EPS (earnings per share)?
ARTELO BIOSCIENCES, INC. (ARTL)'s trailing twelve month EPS is $-3.07 as of 2026-06-30.
What is ARTL's ROE (return on equity)?
ARTELO BIOSCIENCES, INC. (ARTL)'s trailing twelve month Return on Equity (ROE) is -717.29% as of 2026-06-30.
What is ARTL's ROA (return on assets)?
ARTELO BIOSCIENCES, INC. (ARTL)'s trailing twelve month Return on Assets (ROA) is -238.15% as of 2026-06-30.
What is ARTL's ROIC (return on invested capital)?
ARTELO BIOSCIENCES, INC. (ARTL)'s trailing twelve month Return on Invested Capital (ROIC) is -204.74% as of 2024-12-31.
What is ARTL's EV/EBITDA?
ARTELO BIOSCIENCES, INC. (ARTL)'s trailing twelve month EV/EBITDA is -3.33x as of 2026-06-30.